

Phenotypic Characterization of Inflammatory Bowel Disease Biopsies Reveal That Mast Cells Are Significantly Elevated and Activated In Patients with Ulcerative Colitis

Bradford A Youngblood¹, Melina Butuci¹, Tina Davis¹, Alan L Xu¹, Julia Schanin¹, Emily C Brock¹, Bhupinder Singh¹, Henrik S Rasmussen¹, Amy Holman², Richard Drake², Kathryn Peterson², and Ann D Flynn²
¹Allakos Inc. Redwood City, CA; ²University of Utah, UT

BACKGROUND

- Accumulation and activation of mast cells and eosinophils have been implicated in the pathogenesis of several chronic inflammatory gastrointestinal (GI) diseases, including eosinophilic gastrointestinal diseases (EGIDs) and inflammatory bowel disease (IBD)¹
- Despite the strong association of mast cells and eosinophils in IBD, no further characterization of these cells has been performed
- Here, we aimed to quantify and evaluate the activation state of mast cells and eosinophils in colon tissue from IBD or non-diseased control patients as well as quantified the production of cytokines from human colon tissue mast cells

Figure 1. Mast Cells and Eosinophils are Key Drivers of Acute and Chronic Inflammation





Figure 2. Lirontelimumab (AK002) Mechanism of Action



- Siglec-8 is an inhibitory receptor selectively expressed on human eosinophils and mast cells and represents a novel target for the treatment of IBD
- Lirontelimumab (AK002) is a novel, humanized, non-fucosylated IgG1 monoclonal antibody to Siglec-8 that depletes blood eosinophils by antibody dependent cellular cytotoxicity (ADCC) and induces apoptosis of tissue eosinophils
- In addition, lirontelimumab inhibits both IgE-dependent and independent modes of mast cell activation
- Lirontelimumab has recently demonstrated significant symptomatic and histological improvement in a randomized, double-blind placebo-controlled Phase 2 study in patients with eosinophilic gastritis and/or gastroenteritis

METHODS

- Single-cell suspensions were prepared by enzymatic digestion of fresh colon biopsies from patients with IBD or non-diseased control colon tissue
- Multi-color flow cytometry was performed to identify and evaluate the activation state of mast cells and eosinophils
- Mast cells were FACS-sorted from non-diseased human colon tissue to evaluate cytokine production from mast cells after overnight stimulation with PMA/Ionomycin
- The inhibitory activity of lirontelimumab was evaluated using human colon tissue mast cells stimulated with LPS

Figure 3. Study Design




Figure 4. Flow Cytometry Gating Strategy for Mast Cells and Eosinophils in IBD Biopsy Tissue




Figure 5. Mast Cells and Eosinophils are Significantly Elevated in Ulcerative Colitis Biopsies




Figure 5: Percentage of colonic tissue mast cells and eosinophils in biopsy tissue from UC and CD patients or non-diseased control colon tissue. Mast cells and eosinophils were quantified by flow cytometry as shown in Figure 4. Graphs are plotted as the percentage of CD45+ viable cells from individual patients +/- SEM. * p<0.05, ** p<0.01, *** p<0.001 determined by one-way ANOVA with Tukey's multiple comparisons test

- The percentage of mast cells was significantly increased in ulcerative colitis (UC) biopsy tissue compared to Crohn's disease (CD) and non-diseased colon tissue
- In addition, the percentage of eosinophils was significantly increased in UC and nominally elevated in CD biopsy tissue compared to non-diseased colon tissue

Figure 6. Mast Cells in Ulcerative Colitis Tissue Display an Increased Degranulation and Activation State




Figure 6: Expression of the mast cell degranulation marker (CD107a) and surface bound IgE on mast cells in biopsy tissue from UC and CD patients or non-diseased control colon tissue. Data are shown as the mean fluorescence intensity (MFI) from individual patients +/- SEM. * p<0.05, ** p<0.01

- The expression of the mast cell degranulation marker CD107a was significantly increased on mast cells from UC biopsy tissue compared to CD and non-diseased colon tissue mast cells
- However, unlike mast cells in allergic disease, IgE expression was unchanged between UC, CD, and non-diseased colon mast cells which suggest a non-IgE-driven mechanism of mast cell activation in IBD

Figure 7. Eosinophils in Ulcerative Colitis and Crohn's Disease Tissue Display an Increased Activation State




Figure 7: Expression of the eosinophil activation markers, CD11b and CD66b on eosinophils in biopsy tissues from UC and CD patients or non-diseased control colon tissue. Data are shown as the mean fluorescence intensity (MFI) from individual patients +/- SEM. * p<0.05, ** p<0.01

- The expression of the eosinophil activation marker CD11b was significantly increased on both UC and CD tissue eosinophils compared to non-diseased colon tissue eosinophils
- UC biopsy tissue eosinophils also displayed significantly increased expression of CD66b compared to non-diseased colon tissue eosinophils

Figure 8. Siglec-8 is Highly Expressed on Mast Cells and Eosinophils in IBD Tissue




Figure 8: Siglec-8 is selectively expressed on mast cells and eosinophils in all tissues, including IBD biopsies. Mast cells (blue) and eosinophils (red) were identified by flow cytometry as shown in Figure 4.

Figure 9. Human GI Tissue Mast Cells Produce Multiple Pro-Inflammatory Cytokines Associated with IBD




Figure 9: Mast cells were FACS-sorted from non-diseased human colon tissue cultured overnight unstimulated (black) or PMA/Ionomycin stimulated (blue) followed by cytokine analysis in the supernatant. Data are shown as pg/mL/sorted cell number from individual donors +/- SEM. **** p<0.0001

Figure 10. Lirontelimumab (AK002) Suppresses Cytokine Production from Human GI Tissue Mast Cells




Figure 10: Mast cells were isolated using CD117 beads from non-diseased human colon tissue and cultured overnight unstimulated (black) or LPS stimulated in the presence of an isotype control mAb (gray) or Lirontelimumab (blue) followed by cytokine analysis in the supernatant. Data are shown as pg/mL +/- SEM

- Lirontelimumab reduces cytokines associated with driving IBD through mast cell inhibition

CONCLUSIONS/DISCUSSION

- Mast cells and eosinophils may play a significant role in driving the pathogenesis of ulcerative colitis through the production of inflammatory mediators
- Siglec-8 is highly expressed on mast cells and eosinophils in IBD tissue, thus antibodies that target the Siglec-8 receptor, such as lirontelimumab (AK002), represent a potential novel targeted approach to IBD treatment